Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Some Incyte Into Why These Drugs Rock

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Eli Lilly (NYSE: LLY  ) jumped on the oral-drug-for-rheumatoid-arthritis bandwagon yesterday. Joining Pfizer (NYSE: PFE  ) , Rigel Pharmaceuticals, and Lexicon Pharmaceuticals, Eli Lilly licensed a phase 2 drug, INCB28050, from Incyte (Nasdaq: INCY  ) .

Incyte is due $90 million upfront and there's potential for another $665 million in milestone and double-digit royalty payments that could get as high as 20% if the drug is a commercial success.

That's a substantial payout for a drug that hasn't yet proven itself in phase 2 trials, but not all that surprising considering that the rheumatoid arthritis market is huge. One reason: The major competition -- Abbott Labs' (NYSE: ABT  ) Humira, Johnson & Johnson's (NYSE: JNJ) and Merck's (NYSE: MRK  ) Remicade, and Pfizer's (NYSE: PFE  ) and Amgen's (Nasdaq: AMGN  ) Enbrel -- all have to be injected or infused. An oral medication only needs to work as well and be as safe to grab a substantial chunk of the market.

Lilly is taking a bit of a risk at being a latecomer to the party; both Pfizer's CP-690,550 and Rigel's R788 have completed phase 2 trials. Nevertheless, there's no guarantee that they'll make it through the clinical trial process, or past the Food and Drug Administration, so it's still possible for INCB28050 to be the first to market.

For Incyte, much of the value of the company is tied up in its most advanced drug, INCB18424. It licensed the ex-U.S. rights to Novartis last month. The partnership with Lilly may turn out to be fruitful, but investors will have to wait a while to see their oral rheumatoid arthritis drug on the market.

Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is a Income Investor recommendation. Novartis is a Global Gains pick. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1072043, ~/Articles/ArticleHandler.aspx, 10/23/2016 6:11:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
INCY $87.72 Down -0.77 -0.87%
Incyte CAPS Rating: **
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
ABT $40.50 Down -0.24 -0.59%
Abbott Laboratorie… CAPS Rating: *****
AMGN $158.51 Down -2.99 -1.85%
Amgen CAPS Rating: ****
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****